Skip to content

Author

R. Mckay

We have 3 of 70 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

The combination of the ATR inhibitor berzosertib with carboplatin demonstrated a lower ORR and more frequent ≥ grade 3 TrAEs compared with docetaxel + carboplatin in this heavily pretreated, biomarker-unselected mCRPC population.

A. Choudhury, C. Zhong, Wan-Ling Xie et al. · 0 citations
Review Open access Sep 2026

Cardiovascular Risk Triage Schema for Patients With Prostate Cancer Treated With Hormone Therapy.

IMPORTANCE Cardiovascular disease (CVD) is a leading noncancer cause of death among patients with prostate cancer (PC). Population-based risk calculators do not account for treatment-related effects of androgen-deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPis), and they have not been validated...

A. Guha, Ana Barac, M. Ryan et al. · 0 citations
Aug 2026

Longitudinal Phenotyping of Circulating Tumor Cells using a Scalable Deep Learning Framework.

This work developed and clinically validated the System for Enhanced Evaluation of Tumor Cells (SEE-TC), a deep learning approach for scalable, reproducible phenotyping of individual circulating cells that is the first fully automated AI approach to single-cell segmentation and CTC phenotyping.

M. Bootsma, M. Sharifi, J. Sperger et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.